Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | POLB | P06746 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CDC7 | O00311 | 1/20 | 0.55 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14148621 | 0.88 | ALDH1A1 (0.72) | LMNAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL14148652 | 0.87 | MEN1 (0.62) | LMNAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL977661 | 0.86 | CDC7 (0.70) | LMNAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL16038025 | 0.85 | ALDH1A1 (0.60) | LMNAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL14148651 | 0.81 | KMT2A (0.57) | LMNAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL4741747 | 0.79 | MEN1 (0.65) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL13561015 | 0.79 | MEN1 (0.66) | LMNAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL974923 | 0.78 | TRPM8 (0.73) | POLBALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL13576512 | 0.78 | KMT2A (0.79) | LMNAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL12335736 | 0.78 | KMT2A (0.67) | LMNAMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation for Research Development (10 pp.) | 2016-05-12 | — | — | US | claimed |
| US-20140275178-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | claimed |
| US-9850218-B2 | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850218-B2 | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850218-B2 | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation for Research Development (10 pp.) | 2016-05-12 | — | — | US | disclosed |
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation for Research Development (10 pp.) | 2016-05-12 | — | — | US | disclosed |
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation for Research Development (10 pp.) | 2016-05-12 | — | — | US | disclosed |
| WO-2014160197-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275178-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275178-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275178-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2008090382-A1 | THIAZOLE AND OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PRION DISEASES, CANCER AND CONDITIONS OF THE CENTRAL NERVOUS SYSTEM AS WELL AS IN THE REGULATION OF STEM CELLS | THE UNIVERSITY OF SHEFFIELD (GB) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275178-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | TTR, PPARG, PPARD | LMNA 204/4885POLB 1900/4885MEN1 1314/4885 |
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | TTR, PPARG, PPARD | LMNA 204/4885POLB 1900/4885MEN1 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.